Compare Eli Lilly And Co (LLY) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

NNDM trades at $1.545, down 0.32% today, with a bearish technical signal from moving averages. The company reported 2025 revenue of $102.44M but a net loss of $293.30M, reflecting a -286.72% net margin. Cash flow remains negative at -$112.07M, though the balance sheet shows $757.96M in cash against minimal debt. Recent news highlights cost-saving initiatives and a proposed merger with Infinite Epigenetics amid shareholder disputes with Murchinson.

Outlook remains challenged by persistent losses and cash burn, but the strong cash position provides a buffer. The proposed merger introduces strategic uncertainty. Key risks include execution on profitability and shareholder alignment. Analyst sentiment is cautious given the fundamental weaknesses and ongoing corporate actions.